6.00
+0.2(+3.45%)
Currency In USD
| Previous Close | 5.8 |
| Open | 5.8 |
| Day High | 6.07 |
| Day Low | 5.75 |
| 52-Week High | 20.9 |
| 52-Week Low | 5.71 |
| Volume | 498,979 |
| Average Volume | 369,920 |
| Market Cap | 268.73M |
| PE | -11.11 |
| EPS | -0.54 |
| Moving Average 50 Days | 8.44 |
| Moving Average 200 Days | 12.02 |
| Change | 0.2 |
If you invested $1000 in Y-mAbs Therapeutics, Inc. (YMAB) since IPO date, it would be worth $250 as of February 05, 2025 at a share price of $6. Whereas If you bought $1000 worth of Y-mAbs Therapeutics, Inc. (YMAB) shares 5 years ago, it would be worth $176.26 as of February 05, 2025 at a share price of $6.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting
GlobeNewswire Inc.
Jan 31, 2025 12:35 PM GMT
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody
Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities
GlobeNewswire Inc.
Jan 10, 2025 2:26 PM GMT
Company establishes two business units with goal of accelerating clinical development of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA Preliminary Part A data from GD2-SADA Phase 1 trial demonstrates tolerabili
Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit
GlobeNewswire Inc.
Jan 10, 2025 12:35 PM GMT
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody